At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 215 enrolled
Drug / intervention
NPC-01 +2 moredrug
Likely dose
NPC-01 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3, Placebo Controlled, Randomized, Double-blinded, Nonsteroidal Antiinflammatory Drug add-on, Clinical Trial of NPC-01 for Treatment of Dysmenorrhea
In Brief
A Phase 3 clinical trial evaluating NPC-01, IKH-01, and 1 other intervention for Dysmenorrhea. Completed, enrolled 215 participants.
Detailed Summary
The purpose of this study is to determine whether NPC-01 is effective in the treatment of dysmenorrhea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDysmenorrhea
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionApr 2011
TodayJul 2026
First PostedMay 24, 2010
Enrollment StartMay 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.1 years ago
Interventions
NPC-01drug
Norethisterone 1mg, Ethinyl estradiol 0.02mg
IKH-01drug
Norethisterone 1mg, Ethinyl estradiol 0.035mg
Placebodrug
Placebo for NPC-01